Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Bartomeu Fullana
Observed name:
B. Fullana
Institutions:
Institut d'Investigació Biomédica de Bellvitge,
MedSIR (Spain),
Institut Català d'Oncologia
Observed institutions:
Bellvitge University Hospital,
Institut d'Investigació Biomédica de Bellvitge,
MedSIR (Spain),
Institut Català d'Oncologia
ORCID:
0000-0003-3556-6947
Observed ORCID:
0000-0003-3556-6947
OpenAlex ID:
A5099782693
Breast Cancer Patient’s Outcomes after Neoadjuvant Chemotherapy and Surgery at 5 and 10 Years for Stage II–III Disease
2024
·
Catalina Falo
, Juan Azcarate
, et al.
·
Cancers
·
8
Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial
2024
·
Bartomeu Fullana
, Serafín Morales
, et al.
·
Scientific Reports
·
4
Abstract P2-01-16: Pharmacogenomic variants and risk of adverse events in breast cancer patients treated with Trastuzumab-deruxtecan: results from the PROCURE project
2025
·
Rodrigo Sánchez-Bayona
, Javier de Nicolás-Hernández
, et al.
·
Clinical Cancer Research
·
3
A breast tissue-specific epigenetic clock provides accurate chronological age predictions and reveals de-correlation of age and DNA methylation in tumor-adjacent and tumor samples
2026
·
Leonardo D. Garma
, Sonia Pernas
, et al.
·
Epigenetics
·
2
PDF
Longitudinal Clinical, Physiological, and Molecular Profiling of Female Patients With Metastatic Cancer: Protocol and Feasibility of a Multicenter High-Definition Oncology Study
2026
·
Leonardo D. Garma
, Sonia Pernas
, et al.
·
JCO Precision Oncology
·
2
PDF
Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project
2026
·
R. Sánchez-Bayona
, J. de Nicolás-Hernández
, et al.
·
ESMO Open
·
2
Germline pharmacogenetic variants associated with trastuzumab deruxtecan-induced interstitial lung disease in advanced breast cancer: PROCURE project
2026
·
A. Arenas
, C. Saura
, et al.
·
ESMO Open
PDF
The important role of molecular profiling to guide therapy in metastatic breast cancer patients and the emerging role of liquid biopsy in the detection of resistance mechanisms with ultrasensitive techniques
2026
·
C. Falo Zamora
, A. Garcia Bauto
, et al.
·
European Journal of Cancer
Abstract PS4-02-23: Biomarkers of response and resistance to Sacituzumab Govitecan in HR+/HER2− advanced breast cancer: interim results from the phase II SOLTI ACROSS-TROP2 Trial
2026
·
E. Ciruelos
, T. Pascual
, et al.
·
Clinical Cancer Research
Abstract P1-02-17: Rediscovering Denosumab: Immunomodulation of the Tumor Microenvironment in Early-Stage Breast Cancer through RANK Pathway Inhibition
2025
·
Andrea Vethencourt
, Eva M. Trinidad
, et al.
·
Clinical Cancer Research
64P TGFβI promoter hypermethylation as a biomarker of resistance in HER2-positive early breast cancer
2025
·
H. Pla Juher
, A. Roqué Lloveras
, et al.
·
ESMO Open
PDF
Comprehensive Clinical Characterization and Long-Term Follow-Up of the Institut Català d’Oncologia Breast Cancer Observational Cohort Study
2025
·
Helena Pla
, Bartomeu Fullana
, et al.
·
Cancers
PDF
Show more works
View as search
Works count:
12
Citation count:
21
H-index:
3
I10-index:
Year
Topic
Type